OncoMark Ltd. is a private company centred on the development and application of biomarker panels, particularly supporting oncology drug development. A major focus of the company is to provide the link from -omic level discovery to validation via the use of multiplex antibody-based assays and high-throughput tissue microarray screening. OncoMark also conducts in-house research and development to (1) create unique multi-marker assays for use in the discrimination of patient response to drug therapies and (2) apply novel in-house image analysis toolkit for assessment of IHC-based markers at the subcellular compartmental level [IHC-MARK]. This is of particular benefit to the pharmaceutical and health authority sectors.